Cencora Advances Acquisition of OneOncology in $7.4 Billion Transaction

Cencora (NYSE: COR) is moving forward with plans to acquire majority control of OneOncology, a U.S.-based oncology care network, in a transaction that values the business at approximately $7.4 billion. The deal deepens Cencora’s presence in cancer care services and reflects a broader push toward more integrated healthcare delivery models.

Cencora already holds a minority stake in OneOncology and will acquire most of the remaining ownership interests from existing investors, including private equity firm TPG. As part of the transaction, Cencora will also assume a portion of OneOncology’s outstanding debt, with total cash consideration estimated at around $5 billion.

Expanding Beyond Drug Distribution

OneOncology supports a network of independent oncology practices by providing shared services such as data analytics, care coordination, technology platforms, and operational infrastructure. By bringing OneOncology under its control, Cencora aims to expand beyond its traditional role in pharmaceutical distribution and become more directly involved in the delivery and coordination of cancer care.

The move reflects a growing trend across healthcare, where companies are seeking closer alignment between drug supply, clinical services, and patient outcomes—particularly in complex, high-cost areas like oncology.

Financial Impact and Timeline

Cencora expects the transaction to close by the end of its second fiscal quarter of 2026, subject to customary approvals. The company plans to finance the acquisition primarily through new debt and has indicated it will pause share repurchases in the near term as it completes the deal.

While the transaction may place near-term pressure on earnings, Cencora has raised its longer-term profit outlook, citing the expected contribution from OneOncology as the network continues to scale.

Broader Implications for Cancer Care

The acquisition highlights continued consolidation within oncology services, as healthcare providers seek more coordinated, data-driven approaches to treatment delivery. Cancer care often involves complex treatment regimens, high drug costs, and long patient journeys, making integrated service models increasingly attractive.

As demand for oncology services continues to grow, transactions like this underscore how the sector is evolving toward tighter integration between pharmaceutical supply chains and frontline care delivery.